Humacyte Earnings Call Balances Growth With Losses

Humacyte ((HUMA)) has held its Q1 earnings call. Read on for the main highlights of the call.

Humacyte’s latest earnings call painted a cautiously optimistic picture, with solid operational and clinical momentum offset by a sharp reversal in profitability. Management highlighted strong percentage growth in Symvess sales, advancing late-stage trials, and fresh government and international interest, while acknowledging that higher costs, inventory charges, and modest absolute revenues weighed heavily on the bottom line.

Symvess Commercial Growth

Symvess, Humacyte’s flagship vascular conduit, showed early but meaningful commercial traction, with Q1 2026 sales rising to $0.5 million from $0.1 million a year earlier and units jumping to 29 from 5. Management noted sequential unit growth and broader use across more than 30 sites, with signs that surgeons beyond the original adopters are beginning to implant the product.

Dialysis Phase III (V012) Progress and Near-Term Milestone

Enrollment in the V012 Phase III dialysis trial has reached 120 patients, setting the stage for a key interim analysis. Topline data are slated to be presented by June 11, 2026, and if the results are positive, the study will stop per protocol and Humacyte plans to file a supplemental BLA for the dialysis indication in the second half of 2026.

CTEV (Coronary Tissue Engineered Vessel) Advancement

Humacyte is advancing its coronary tissue engineered vessel program, having submitted an IND in late 2025 and moving toward completion of its first large-scale manufacturing lot in the commercial facility. A Phase I/II CABG trial using 3.5 mm coronary-tailored vessels is targeted to begin in the second half of 2026, positioning CTEV as a longer-term growth driver.

Commercial Leadership Strengthening

To accelerate product uptake, the company has upgraded its commercial bench, appointing James Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer. Humacyte also expanded its field commercial team, with a focus on integrated delivery networks and surgeon education to ensure Symvess moves from hospital shelves into routine clinical use.

International and Strategic Engagements

Internationally, Humacyte’s market access agenda gained traction as Israel accepted its marketing application for a 180 working-day review. The company also announced a $1.475 million purchase commitment from Saudi Arabia to support clinical evaluation and outreach and highlighted dedicated support from the U.S. Department of Defense alongside regained ex-U.S. rights to pursue opportunities in the Middle East, Europe, and Japan.

Restructuring, Cost Savings and Cash Position

Humacyte launched a restructuring that cuts about 25% of its workforce, or 45 employees, aiming to concentrate resources on commercialization and core programs. The move carries roughly $0.8 million in one-time severance costs, mostly in Q2, but is expected to generate about $14.3 million in net savings over the rest of 2026, while the company ended Q1 with $48.9 million in cash and restricted cash and net cash use of $2.0 million.

Swing to Net Loss

The company’s income statement showed a dramatic reversal, with a Q1 2026 net loss of $17.6 million versus net income of $39.1 million in the prior-year quarter. This $56.7 million swing reflects both weaker noncash other income and growing operating spend as Humacyte scales manufacturing and advances its pipeline.

Sharp Decline in Other Net Income

Other net income fell steeply to $11.3 million in Q1 2026 from $62.3 million a year earlier, an approximately 82% decline. The drop was driven mainly by a lower noncash benefit from remeasuring a contingent earn-out liability, meaning reported profitability deteriorated for reasons that do not directly reflect core cash operations but still matter to headline results.

Large Increase in Cost of Goods Sold Driven by Inventory Reserve

Cost of goods sold surged to $2.0 million in Q1 2026 from just $0.1 million a year prior, outpacing the current scale of product sales. Only $0.2 million of COGS was tied to units actually sold, while a $1.6 million inventory reserve related to writing stock down to net realizable value and overhead from unused manufacturing capacity weighed heavily on gross margin.

Contract Research Revenue Decrease

Contract research revenue almost disappeared, dropping to roughly $2,000 in Q1 2026 from $0.4 million in the same period last year. Management attributed the plunge to the completion of a phase of work under a collaboration with a large medical technology partner, removing a small but previously recurring revenue stream.

Elevated R&D Spend

Research and development expenses climbed to $19.5 million in Q1 2026 from $15.4 million in Q1 2025, an increase of around 27%. The rise was fueled by about $4.3 million in material costs tied to noncommercial CTEV manufacturing runs and process improvements, which intensify near-term cash burn but are necessary to enable upcoming clinical studies.

Commercial Revenue Still Modest and Uptake Needs Acceleration

Despite impressive percentage growth, Symvess remains a small revenue contributor at $0.5 million for the quarter, and management admitted that adoption still needs to accelerate meaningfully. The product is already listed at some hospitals, but inconsistent pull-through has been blamed on earlier gaps in surgeon support, which the new commercial strategy aims to correct.

One-Time Restructuring Costs and Timing Uncertainties

The restructuring initiative introduces some execution risk, with roughly $0.8 million in one-time severance costs and uncertainty over when the projected $14.3 million in savings will fully materialize. Management also acknowledged that timelines for regulatory decisions and potential U.S. government procurement remain difficult to predict, adding a layer of timing risk to the commercial ramp.

Forward-Looking Guidance and Milestones

Formal revenue guidance for 2026 was limited, but management outlined key operational markers including Q1 Symvess sales of $0.5 million on 29 units and a leaner cost base following the workforce reduction. Looking ahead, investors will be watching the V012 interim readout by June 11, 2026, a potential supplemental BLA filing in the second half, Israel’s regulatory review, initiation of the first-in-human CTEV CABG study in the second half of 2026, and the company’s plan to provide fuller 2026 guidance by year-end.

Humacyte’s call showcased a company in transition, with growing commercial activity, late-stage clinical catalysts, and strategic partnerships building a stronger long-term story. At the same time, the swing to a sizable net loss, higher R&D and COGS, and still-modest revenue base mean investors will need to balance near-term financial pressure against the potential upside from upcoming trial data and regulatory milestones.